Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 Earnings Call Transcript March 23, 2026 Bionano Genomics, Inc. reports earnings inline with expectations. Reported EPS is $-2.475 EPS, expectations were ...

Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping (OGM) can significantly outperform ...

Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is getting leaner while its technology goes deeper into the clinical mainstream.

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due ...

Bionano says it expects another quarter of revenue growth. The company makes genomic testing equipment. Bionano has been consistently unprofitable. Bionano said it expected revenue of $7.3 million to ...

Bionano Genomics, Inc. today announced the Stratys ™ system for high throughput optical genome mapping (OGM) and VIA ™ software for visualization, interpretation and reporting of genome analysis for ...

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025.

26 different customers representing North America, Asia and Europe 33 oral presentations across four consecutive days 69 scientific posters will be featured in a virtual exhibition hall Topics span ...

Bionano Genomics (NASDAQ:BNGO) is a life sciences instrumentation company focused on the genome analysis space. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data ...

Full year revenue guidance remains $26 million to $30 million, with third quarter revenue expected between $6.7 million and $7.2 million. The company raised its OGM installation guidance for 2025 from ...